Literature DB >> 22965507

Sclerotherapy of simple hepatic cysts by repeated aspiration and alcohol instillation.

Feng Yan-Hong1, Qian Lin-Xue, Gong Hai-Ma, Zhang Qing, Gui Yu, Hu Xiangdong.   

Abstract

BACKGROUND/AIMS: The efficacy and safety of traditional alcohol sclerotherapy procedures are controversial in the management of large simple hepatic cysts. In this study, we aimed to develop and evaluate a novel alcohol sclerotherapy procedure, termed repeated aspiration and alcohol instillation sclerotherapy, for the treatment of simple hepatic cysts.
MATERIALS AND METHODS: A prospective, double-blind, randomized study was performed. Sixty-seven patients with large simple hepatic cysts were randomized into two groups to receive either single-session alcohol retention sclerotherapy (alcohol was instilled into the cyst cavity, kept for 20 minutes and aspirated) or repeated aspiration and alcohol instillation sclerotherapy (instillation of 30-70 ml of alcohol and immediate aspiration with repetition 3 to 6 times until the estimated alcohol concentration exceeded 80%). The cyst volume reduction was calculated to compare the efficacy of the two procedures. We evaluated the safety of the procedure by monitoring side effects and assaying blood alcohol concentrations at 0, 0.5, 1, 2 and 3 hours after sclerotherapy.
RESULTS: The cyst volume reduction in patients undergoing repeated aspiration and alcohol instillation sclerotherapy was significantly higher than that in those receiving alcohol-retention sclerotherapy. The concentration of alcohol in the last aspirated cyst fluid was correlated with the mean volume reduction in patients undergoing repeated aspiration and alcohol instillation sclerotherapy but not in the alcohol-retention group. Only minor side effects occurred in both groups. Although elevated blood alcohol concentration was noted in all patients, it declined to normal levels within 2-3 hours after treatment. There were no significant differences in blood alcohol concentration between the two groups.
CONCLUSIONS: Repeated aspiration and alcohol instillation sclerotherapy is superior to single-session alcohol-retention sclerotherapy in the management of large simple hepatic cysts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965507     DOI: 10.4318/tjg.2012.0349

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  6 in total

1.  Alcoholization of pyogenichepatic abscess with absolute alcohol in Bama minipigs.

Authors:  Ru-Gang Zhang; Xiu-Li Zhang; Yun-Sheng Yang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

2.  Single-session alcohol sclerotherapy of symptomatic liver cysts using 10-20 min of ethanol exposure: no recurrence at 2-16 years of follow-up.

Authors:  Trond Bjerke Larssen; Asgaut Viste; Arild Horn; Ingfrid Salvesen Haldorsen; Ansgar Espeland
Journal:  Abdom Radiol (NY)       Date:  2016-09

3.  Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts.

Authors:  Myrte K Neijenhuis; Titus F M Wijnands; Wietske Kievit; Maxime Ronot; Tom J G Gevers; Joost P H Drenth
Journal:  Eur Radiol       Date:  2018-12-12       Impact factor: 5.315

4.  Comparison of the Efficacy and Safety of Single-Session OK-432 and Multiple-Session 99% Ethanol Sclerotherapy for Symptomatic Simple Hepatic Cysts.

Authors:  Zhiqiang Mo; Fangfang Yang; Ling Lv; Jian He; Qin Gou; Xiaoming Chen; Wenhang Zhuang; Qicong Mai
Journal:  Front Med (Lausanne)       Date:  2022-07-15

5.  Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data.

Authors:  Titus F M Wijnands; Maxime Ronot; Tom J G Gevers; Julie Benzimra; Leo J Schultze Kool; Valérie Vilgrain; Joost P H Drenth
Journal:  Eur Radiol       Date:  2016-05-14       Impact factor: 5.315

6.  Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts.

Authors:  Titus Fm Wijnands; Bastian Schoenemeier; Andrej Potthoff; Tom Jg Gevers; Hans Groenewoud; Michael J Gebel; Kinan Rifai; Michael P Manns; Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2018-03-08       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.